"Presenting clinical data at both AACR and AAN underscores the breadth of the DOC1021 platform across multiple hard-to-treat cancers with significant unmet need," said Jay Hartenbach, President and ...
DOC1021 is now also enrolling in a refractory melanoma clinical study, targeting a population with limited options after anti-PD-1 failure. "ASCO provides an important opportunity to share the ...
HOUSTON--(BUSINESS WIRE)--Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that it will present at the Emerging Growth Conference on Wednesday, ...
NTRA will deploy Signatera in Diakonos' DOC-RM Phase I/II trial for refractory melanoma. Signatera will track ctDNA over multiple timepoints as DOC1021 tests dendritic cell immunotherapy. NTRA stock ...
HOUSTON--(BUSINESS WIRE)--Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
Signatera™ to evaluate molecular response to investigational dendritic cell therapy as part of Diakonos’ Phase I/II trial Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision ...
Recent Clinical Data for Dubodencel (DOC1021) in Glioblastoma Drive Financing with Backing from Baylor College of Medicine and The Brain Tumor Investment Fund HOUSTON, May 30, 2025 /PRNewswire/ -- ...
The MarketWatch News Department was not involved in the creation of this content. -- At $11.4M, the oversubscribed financing is expected to fund operations into late 2025. -- Topline safety and ...
HOUSTON, March 18, 2026 /PRNewswire/ -- Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, ...
Diakonos also received Orphan Drug Designation for the GBM program in January 2024. About Diakonos Oncology Corp. Based in Houston, TX, Diakonos Oncology Corp. is a clinical-stage biotechnology ...
Natera NTRA recently announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results